Article Details

AstraZeneca's Alexion buy takes first hit as Ultomiris fails in rare neurodegenerative disease

Retrieved on: 2021-08-20 15:24:12

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Alexion buy takes first hit as Ultomiris fails in rare neurodegenerative disease. View article details on hiswai:

Excerpt

Bad news has struck first for AstraZeneca's newly acquired Alexion rare disease franchise. AstraZeneca has decided to cap a phase 3 trial testing C5 inhibitor ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up